Estil Vance

1.3k total citations
27 papers, 929 citations indexed

About

Estil Vance is a scholar working on Epidemiology, Oncology and Hematology. According to data from OpenAlex, Estil Vance has authored 27 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Oncology and 8 papers in Hematology. Recurrent topics in Estil Vance's work include Multiple Myeloma Research and Treatments (5 papers), Acute Myeloid Leukemia Research (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Estil Vance is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Acute Myeloid Leukemia Research (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Estil Vance collaborates with scholars based in United States and South Africa. Estil Vance's co-authors include Michael Boeckh, Genovefa A. Papanicolaou, Drew J. Winston, Alice Robertson, Francisco M. Marty, Scott D. Rowley, Thomas M. Brundage, Kathleen M. Mullane, Herve Momméja-Marin and David Oldach and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Estil Vance

26 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Estil Vance United States 12 688 223 209 136 73 27 929
Nicolas C. Issa United States 18 551 0.8× 307 1.4× 183 0.9× 107 0.8× 146 2.0× 57 978
P Dentico Italy 21 1.3k 1.8× 231 1.0× 107 0.5× 44 0.3× 125 1.7× 72 1.7k
Toshio Minematsu Japan 18 708 1.0× 391 1.8× 124 0.6× 89 0.7× 166 2.3× 49 1.0k
Sanjeet Dadwal United States 20 730 1.1× 548 2.5× 350 1.7× 256 1.9× 121 1.7× 91 1.3k
K. A. Sepkowitz United States 15 504 0.7× 467 2.1× 176 0.8× 100 0.7× 38 0.5× 20 843
Véronique Venard France 19 888 1.3× 407 1.8× 195 0.9× 59 0.4× 63 0.9× 40 1.4k
Herve Momméja-Marin United States 14 918 1.3× 493 2.2× 222 1.1× 58 0.4× 35 0.5× 32 1.3k
Jeffrey A. DesJardin United States 10 547 0.8× 105 0.5× 181 0.9× 66 0.5× 21 0.3× 11 792
Estela Giménez Spain 22 846 1.2× 516 2.3× 297 1.4× 184 1.4× 207 2.8× 117 1.4k
Jérôme Le Goff France 15 428 0.6× 407 1.8× 109 0.5× 52 0.4× 126 1.7× 50 930

Countries citing papers authored by Estil Vance

Since Specialization
Citations

This map shows the geographic impact of Estil Vance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Estil Vance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Estil Vance more than expected).

Fields of papers citing papers by Estil Vance

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Estil Vance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Estil Vance. The network helps show where Estil Vance may publish in the future.

Co-authorship network of co-authors of Estil Vance

This figure shows the co-authorship network connecting the top 25 collaborators of Estil Vance. A scholar is included among the top collaborators of Estil Vance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Estil Vance. Estil Vance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2024). Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. Blood Advances. 9(2). 429–435. 4 indexed citations
2.
Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S55–S55. 2 indexed citations
3.
Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S211–S211.
4.
Krause, John R., et al.. (2014). Multicentric Castleman's Disease and Hiv. Baylor University Medical Center Proceedings. 27(1). 28–30. 3 indexed citations
5.
Marty, Francisco M., Drew J. Winston, Scott D. Rowley, et al.. (2013). CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 369(13). 1227–1236. 267 indexed citations
6.
7.
Agura, E.D., R.B. Berryman, Breanna Cooper, et al.. (2007). Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Journal of Clinical Oncology. 25(18_suppl). 7064–7064. 2 indexed citations
8.
9.
Winston, Drew J., Jo‐Anne van Burik, Vinod Pullarkat, et al.. (2006). Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.. Blood. 108(11). 593–593. 5 indexed citations
10.
11.
Saracino, Giovanna, R.B. Berryman, JW Fay, et al.. (2005). Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplantation. 35(8). 747–754. 16 indexed citations
12.
Cather, Jennifer Clay, Estil Vance, & Alan Menter. (2002). Diverse Cutaneous Manifestations Associated with a Single Disease. Baylor University Medical Center Proceedings. 15(4). 433–436. 2 indexed citations
13.
14.
Kulke, Matthew H. & Estil Vance. (1997). Pneumocystis cariniiPneumonia in Patients Receiving Chemotherapy for Breast Cancer. Clinical Infectious Diseases. 25(2). 215–218. 40 indexed citations
15.
Auwaerter, Paul G., David Oldach, Linda M. Mundy, et al.. (1996). Hantavirus Serologies in Patients Hospitalized with Community-Acquired Pneumonia. The Journal of Infectious Diseases. 173(1). 237–239. 4 indexed citations
16.
Vance, Estil, Robert J. Soiffer, George B. McDonald, et al.. (1996). PREVENTION OF TRANSMISSION OF HEPATITIS C VIRUS IN BONE MARROW TRANSPLANTATION BY TREATING THE DONOR WITH??-INTERFERON1. Transplantation. 62(9). 1358–1360. 25 indexed citations
17.
Mundy, Linda M., Paul G. Auwaerter, David Oldach, et al.. (1995). Community-Acquired Pneumonia: Impact of Immune Status. American Journal of Respiratory and Critical Care Medicine. 152(4). 1309–1315. 147 indexed citations
18.
Gaydos, C A, Joseph Eiden, David Oldach, et al.. (1994). Diagnosis of Chlamydia pneumoniae Infection in Patients with Community-Acquired Pneumonia by Polymerase Chain Reaction Enzyme Immunoassay. Clinical Infectious Diseases. 19(1). 157–160. 54 indexed citations
19.
20.
Hantel, Alexander, Ross C. Donehower, Eric K. Rowinsky, et al.. (1990). Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.. PubMed. 50(11). 3284–8. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas C. Issa Breakdown of academic impact, for papers by P Dentico Breakdown of academic impact, for papers by Toshio Minematsu Breakdown of academic impact, for papers by Sanjeet Dadwal Breakdown of academic impact, for papers by K. A. Sepkowitz Breakdown of academic impact, for papers by Véronique Venard Breakdown of academic impact, for papers by Herve Momméja-Marin Breakdown of academic impact, for papers by Jeffrey A. DesJardin Breakdown of academic impact, for papers by Estela Giménez Breakdown of academic impact, for papers by Jérôme Le Goff
Rankless by CCL
2026